- Discover CFAR
- Find a Service
- Find Funding
- News & Events
- Get Involved
Location: Sze Conference Room, Fred Hutchinson Cancer Research Center
Florian Hladik, MD, PhD
University of Washington/Fred Hutchinson Cancer Research Center
Leading in with a personalized overview of where we currently stand with our knowledge of how HIV and the genital immune system interact, I will discuss some of the recent HIV prevention trials and how these have led to an increased emphasis on assessing mucosal immune responses going forward. New technologies for measuring mucosal immunity to vaccination will be presented.
Florian Hladik obtained his M.D., Ph.D. and dermatology training at the University of Vienna in Austria. He carried out postdoctoral research at the Johannes Gutenberg University in Mainz, Germany, and the University of Washington, USA. He is currently Research Assistant Professor in the Departments of Gynecology and Medicine, University of Washington, and Affiliate Investigator at the Fred Hutchinson Cancer Research Center in Seattle, USA. His research focuses on mucosal HIV transmission pathogenesis, microbicide development and genital immunity in general.
Currently, he is PI of an R21 award examining the effects of exosomes in semen on HIV transmission and immunity in the female genital tract, co-PI of an R21/R33 award aiming to develop nanoparticles for the topical delivery of combination microbicides, and PI of two HVTN-sponsored collaborations evaluating various genital specimen types for the measurement of HIV vaccine-specific immune responses and establishing rational cryopreserveation techniques for mucosal tissues Also for the HVTN, he designs and supervises in situ fluorescence studies analyzing HIV-susceptible target cell populations in the rectal and genital mucosa following HIV vaccination. As Co-Director of the Immunology Core for the Microbicide Trials Network, he advises the MTN on immunologic studies and guides immune assays and gene expression screening in women and men participating in microbicide trials.